Shares of Amgen Inc. (NASDAQ:AMGN) have been given a consensus recommendation of “Buy” by the twenty-seven research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $186.10.
A number of analysts recently weighed in on the stock. Mizuho set a $195.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. UBS AG reissued a “neutral” rating and set a $174.00 price target (down from $175.00) on shares of Amgen in a research report on Monday, May 22nd. Jefferies Group LLC reissued a “buy” rating and set a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. Argus increased their price target on shares of Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Finally, BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down previously from $200.00) on shares of Amgen in a report on Monday, May 22nd.
Amgen (AMGN) opened at 170.04 on Friday. Amgen has a 12 month low of $133.64 and a 12 month high of $184.21. The stock has a market capitalization of $124.07 billion, a PE ratio of 15.49 and a beta of 1.35. The company’s 50-day moving average is $174.35 and its 200-day moving average is $167.93.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the firm earned $2.84 earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities research analysts forecast that Amgen will post $12.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.71%. Amgen’s payout ratio is currently 41.93%.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of AMGN. TrimTabs Asset Management LLC raised its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new position in Amgen during the fourth quarter valued at approximately $102,000. Alpha Omega Wealth Management LLC raised its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Finally, American Beacon Advisors Inc. bought a new position in Amgen during the first quarter valued at approximately $106,000. Institutional investors and hedge funds own 79.12% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/amgen-inc-amgn-given-consensus-recommendation-of-buy-by-brokerages-updated-updated-updated/1249946.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.